申请人:GEORGE MASON UNIVERSITY
公开号:US10927155B2
公开(公告)日:2021-02-23
In one aspect, the invention relates to compositions comprising peptides and/or peptidomimetic compounds, methods of making same, pharmaceutical compositions comprising same, and methods of treating various diseases, including, but not limited to, arthritis, obstructive lung disease, psoriasis, asthma, a defect in hematopoiesis, a neoplasia, a fungal infection, a parasitic infection, or an autoimmune disease, such as, but not limited to, rheumatoid arthritis, atopic allergy, anaphylaxis, psoriasis, asthma, lupus erythematosis, a myeloid cell disorder, or a eosinophil cell disorder. In an aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the ST2 and IL33 receptor/cytokine complexes. In a further aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the IL-1R1 and IL-1β receptor/cytokine complexes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
在一个方面,本发明涉及包含肽和/或仿肽化合物的组合物、其制造方法、包含其的药物组合物以及治疗各种疾病的方法,这些疾病包括但不限于关节炎、阻塞性肺病、银屑病、哮喘、造血缺陷、肿瘤、真菌感染、寄生虫感染或自身免疫性疾病,例如但不限于类风湿性关节炎、哮喘、造血缺陷、肿瘤、真菌感染、寄生虫感染或自身免疫性疾病,例如但不限于类风湿性关节炎、特应性过敏、过敏性休克、银屑病、哮喘、红斑狼疮、髓细胞疾病或嗜酸性粒细胞疾病。在一个方面,所公开的肽和/或化合物可抑制 IL-1RAcP 与 ST2 和 IL33 受体/细胞因子复合物的相互作用。再一方面,所公开的肽和/或化合物抑制 IL-1RAcP 与 IL-1R1 和 IL-1β 受体/细胞因子复合物的相互作用。本摘要旨在作为一种扫描工具,用于特定技术领域的检索,并非对本发明的限制。